Here is yet another, retrospective study drawn from the massive Veteran’s Administration database in the USA. The data were from men with prostate cancer on ADT, of which over 53,000 were taking a statin drug and some 34,000 were not. The researchers found that statin use was an independent predictor of overall survival, prostate cancer specific survival, and a delay in the emergence of symptoms from cancer in the bones. This was after controlling for age, race, comorbidities, PSA levels, and Gleason score.
This is the largest study so far showing a benefit of adding a statin to ADT. It makes a strong case for including a statin drug, which, as a class, are generally inexpensive and relatively risk free drugs, to standard ADT.
To read the study abstract, please see:
Anderson-Carter, I., Posielski, N., Liou, J. I., Khemees, T. A., Downs, T. M., Abel, E. J., Jarrard, D. F., & Richards, K. A. (2018). The impact of statins in combination with androgen deprivation therapy in patients with advanced prostate cancer: A large observational study. Urologic Oncoogy, pii: S1078-1439(18)30465-4. doi: 10.1016/j.urolonc.2018.11.017. [Epub ahead of print]